Các chất ức chế hệ renin-angiotensin cải thiện khả năng sống sót của bệnh nhân ung thư biểu mô đường mật: một nghiên cứu đồng nhóm khớp theo điểm xu hướng

Munugala N, Maithel SK, Shroff RT. Novel biomarkers and the future of targeted therapies in cholangiocarcinoma: a narrative review. Hepatobiliary Surg Nutr. 2022;11:253–66. https://doi.org/10.21037/hbsn-20-475. Halder R, Amaraneni A, Shroff RT. Cholangiocarcinoma: a review of the literature and future directions in therapy. Hepatobiliary Surg Nutr. 2022;11:555–66. https://doi.org/10.21037/hbsn-20-396. Hu LS, Zhang XF, Weiss M, Popescu I, Marques HP, Aldrighetti L, Maithel SK, Pulitano C, Bauer TW, Shen F, et al. Recurrence patterns and timing courses following curative-intent resection for Intrahepatic Cholangiocarcinoma. Ann Surg Oncol. 2019;26:2549–57. https://doi.org/10.1245/s10434-019-07353-4. Zhang XF, Beal EW, Bagante F, Chakedis J, Weiss M, Popescu I, Marques HP, Aldrighetti L, Maithel SK, Pulitano C, et al. Early versus late recurrence of intrahepatic cholangiocarcinoma after resection with curative intent. Br J Surg. 2018;105:848–56. https://doi.org/10.1002/bjs.10676. Merath K, Mehta R, Hyer JM, Bagante F, Sahara K, Alexandrescu S, Marques HP, Aldrighetti L, Maithel SK, Pulitano C, et al. Impact of body mass index on tumor recurrence among patients undergoing curative-intent resection of intrahepatic cholangiocarcinoma- a multi-institutional international analysis. Eur J Surg Oncol. 2019;45:1084–91. https://doi.org/10.1016/j.ejso.2019.03.004. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362:1273–81. https://doi.org/10.1056/NEJMoa0908721. Palmer WC, Patel T. Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma. J Hepatol. 2012;57:69–76. https://doi.org/10.1016/j.jhep.2012.02.022. Clements O, Eliahoo J, Kim JU, Taylor-Robinson SD, Khan SA. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a systematic review and meta-analysis. J Hepatol. 2020;72:95–103. https://doi.org/10.1016/j.jhep.2019.09.007. Helmy A, Jalan R, Newby DE, Hayes PC, Webb DJ. Role of angiotensin II in regulation of basal and sympathetically stimulated vascular tone in early and advanced cirrhosis. Gastroenterology. 2000;118:565–72. https://doi.org/10.1016/s0016-5085(00)70263-0. Powell EE, Edwards-Smith CJ, Hay JL, Clouston AD, Crawford DH, Shorthouse C, Purdie DM, Jonsson JR. Host genetic factors influence disease progression in chronic hepatitis C. Volume 31. Hepatology; 2000. pp. 828–33. https://doi.org/10.1053/he.2000.6253. Okamoto K, Tajima H, Nakanuma S, Sakai S, Makino I, Kinoshita J, Hayashi H, Nakamura K, Oyama K, Nakagawara H, et al. Angiotensin II enhances epithelial-to-mesenchymal transition through the interaction between activated hepatic stellate cells and the stromal cell-derived factor-1/CXCR4 axis in intrahepatic cholangiocarcinoma. Int J Oncol. 2012;41:573–82. https://doi.org/10.3892/ijo.2012.1499. Okamoto K, Tajima H, Ohta T, Nakanuma S, Hayashi H, Nakagawara H, Onishi I, Takamura H, Ninomiya I, Kitagawa H, et al. Angiotensin II induces tumor progression and fibrosis in intrahepatic cholangiocarcinoma through an interaction with hepatic stellate cells. Int J Oncol. 2010;37:1251–9. https://doi.org/10.3892/ijo_00000776. Zhang X, Wong GL, Yip TC, Tse YK, Liang LY, Hui VW, Lin H, Li GL, Lai JC, Chan HL, et al. Angiotensin-converting enzyme inhibitors prevent liver-related events in nonalcoholic fatty liver disease. Hepatology. 2022;76:469–82. https://doi.org/10.1002/hep.32294. Wadsworth BJ, Cederberg RA, Lee CM, Firmino NS, Franks SE, Pan J, Colpo N, Lin KS, Benard F, Bennewith KL. Angiotensin II type 1 receptor blocker telmisartan inhibits the development of transient hypoxia and improves tumour response to radiation. Cancer Lett. 2020;493:31–40. https://doi.org/10.1016/j.canlet.2020.07.015. Hafezi-, Nejad N, Bailey CR, Areda MA, Lafaro KJ, Liddell RP, Holly BP, Weiss CR. Characteristics and outcomes of percutaneous biliary interventions in the United States. J Am Coll Radiol. 2021;18:1059–68. https://doi.org/10.1016/j.jacr.2021.03.010. Mao J, Yang X, Lin J, Yang X, Wang D, Zhang L, Bai Y, Bian J, Long J, Xie F, et al. Apatinib as non-first-line treatment in patients with Intrahepatic Cholangiocarcinoma. J Cancer. 2021;12:1555–62. https://doi.org/10.7150/jca.53482. Lee S, Shroff RT, Makawita S, Xiao L, De Danner A, Bhosale P, Reddy K, Shalaby A, Raghav K, Pant S, et al. Phase II study of Ramucirumab in Advanced biliary tract Cancer previously treated by gemcitabine-based chemotherapy. Clin Cancer Res. 2022;28:2229–36. https://doi.org/10.1158/1078-0432.CCR-21-3548. Zhang G, Gong S, Pang L, Hou L, He W. Efficacy and safety of Apatinib Treatment for Advanced Cholangiocarcinoma after failed gemcitabine-based chemotherapy: an open-label phase II prospective study. Front Oncol. 2021;11:659217. https://doi.org/10.3389/fonc.2021.659217. Mei K, Qin S, Chen Z, Liu Y, Wang L, Zou J. Camrelizumab in combination with apatinib in second-line or above therapy for advanced primary liver cancer: cohort a report in a multicenter phase Ib/II trial. J Immunother Cancer. 2021;9. https://doi.org/10.1136/jitc-2020-002191. Pardo F, Sangro B, Lee RC, Manas D, Jeyarajah R, Donckier V, Maleux G, Pinna AD, Bester L, Morris DL, et al. The Post-SIR-Spheres surgery study (P4S): retrospective analysis of Safety following hepatic resection or transplantation in patients previously treated with Selective Internal Radiation Therapy with Yttrium-90 Resin Microspheres. Ann Surg Oncol. 2017;24:2465–73. https://doi.org/10.1245/s10434-017-5950-z. Xiong J, Lu X, Xu W, Bai Y, Huang H, Bian J, Zhang L, Long J, Xu Y, Wang Z, et al. Metabolic syndrome and the risk of cholangiocarcinoma: a hospital-based case-control study in China. Cancer Manag Res. 2018;10:3849–55. https://doi.org/10.2147/CMAR.S175628. Qu WF, Zhou PY, Liu WR, Tian MX, Jin L, Jiang XF, Wang H, Tao CY, Fang Y, Zhou YF, et al. Age-adjusted Charlson Comorbidity Index predicts survival in intrahepatic cholangiocarcinoma patients after curative resection. Ann Transl Med. 2020;8:487. https://doi.org/10.21037/atm.2020.03.23. Nishioka T, Kubo S, Tanaka S, Wakasa K, Takemura S, Kinoshita M, Hamano G, Kuwae Y, Shibata T, Suehiro S. Outcomes of hepatic resection in Intrahepatic Cholangiocarcinoma patients with diabetes, hypertension, and Dyslipidemia: significance of Routine Follow-Up. Liver Cancer. 2016;5:107–20. https://doi.org/10.1159/000367752. Jothimani D, Venugopal R, Abedin MF, Kaliamoorthy I, Rela M. COVID-19 and the liver. J Hepatol. 2020;73:1231–40. https://doi.org/10.1016/j.jhep.2020.06.006. Meiners J, Jansen K, Gorbokon N, Buscheck F, Luebke AM, Kluth M, Hube-Magg C, Hoflmayer D, Weidemann S, Fraune C, et al. Angiotensin-converting enzyme 2 protein is overexpressed in a wide range of human Tumour types: a systematic tissue microarray study on > 15,000 tumours. Biomedicines. 2021;9. https://doi.org/10.3390/biomedicines9121831. Beyazit Y, Purnak T, Suvak B, Kurt M, Sayilir A, Turhan T, Tas A, Torun S, Celik T, Ibis M, et al. Increased ACE in extrahepatic cholangiocarcinoma as a clue for activated RAS in biliary neoplasms. Clin Res Hepatol Gastroenterol. 2011;35:644–9. https://doi.org/10.1016/j.clinre.2011.06.008. Lu Q, Zhang Y, Geng T, Yang K, Guo K, Min X, He M, Guo H, Zhang X, Yang H, et al. Association of Lifestyle factors and antihypertensive medication Use with risk of all-cause and cause-specific mortality among adults with hypertension in China. JAMA Netw Open. 2022;5:e2146118. https://doi.org/10.1001/jamanetworkopen.2021.46118. Wang L, Hu D, Fan Z, Yu J, Zhang S, Lin Y, Chen X, Lin X, Yan X, Lin J, et al. Prognostic value of long-term antidiabetic and antihypertensive therapy in postoperative gastric cancer patients: the FIESTA study. BMC Gastroenterol. 2022;22:429. https://doi.org/10.1186/s12876-022-02514-4. Li J, Lam ASM, Yau STY, Yiu KKL, Tsoi KKF. Antihypertensive treatments and risks of lung Cancer: a large population-based cohort study in Hong Kong. BMC Cancer. 2021;21:1202. https://doi.org/10.1186/s12885-021-08971-6. Fan Y, Khan NH, Farhan Ali Khan M, Ahammad MDF, Zulfiqar T, Virk R, Jiang E. Association of hypertension and breast Cancer: antihypertensive drugs as an effective adjunctive in breast Cancer therapy. Cancer Manag Res. 2022;14:1323–9. https://doi.org/10.2147/CMAR.S350854. Xie Y, Wang M, Xu P, Deng Y, Zheng Y, Yang S, Wu Y, Zhai Z, Zhang D, Li N, et al. Association between antihypertensive medication use and breast Cancer: a systematic review and Meta-analysis. Front Pharmacol. 2021;12:609901. https://doi.org/10.3389/fphar.2021.609901. Bian S, Dong H, Zhao L, Li Z, Chen J, Zhu X, Qiu N, Jia X, Song W, Li Z, et al. Antihypertension Nanoblockers increase Intratumoral Perfusion of Sequential cytotoxic nanoparticles to Enhance Chemotherapy Efficacy against Pancreatic Cancer. Adv Sci (Weinh). 2022;9:e2201931. https://doi.org/10.1002/advs.202201931. Balkrishnan R, Desai RP, Narayan A, Camacho FT, Flausino LE, Chammas R. Associations between initiating antihypertensive regimens on stage I-III colorectal cancer outcomes: a Medicare SEER cohort analysis. Cancer Med. 2021;10:5347–57. https://doi.org/10.1002/cam4.4088. Matsui S, Sobue T, Zha L, Kitamura T, Sawada N, Iwasaki M, Shimazu T, Tsugane S. Long-term antihypertensive drug use and risk of cancer: the Japan Public Health Center-based prospective study. Cancer Sci. 2021;112:1997–2005. https://doi.org/10.1111/cas.14870. Drucker AM, Hollestein L, Na Y, Weinstock MA, Li WQ, Abdel-Qadir H, Chan AW. Association between antihypertensive medications and risk of skin cancer in people older than 65 years: a population-based study. CMAJ. 2021;193:E508–16. https://doi.org/10.1503/cmaj.201971. Xie Y, Xu P, Wang M, Zheng Y, Tian T, Yang S, Deng Y, Wu Y, Zhai Z, Hao Q, et al. Antihypertensive medications are associated with the risk of kidney and bladder cancer: a systematic review and meta-analysis. Aging. 2020;12:1545–62. https://doi.org/10.18632/aging.102699. Su KA, Habel LA, Achacoso NS, Friedman GD, Asgari MM. Photosensitizing antihypertensive drug use and risk of cutaneous squamous cell carcinoma. Br J Dermatol. 2018;179:1088–94. https://doi.org/10.1111/bjd.16713. Cho IJ, Shin JH, Jung MH, Kang CY, Hwang J, Kwon CH, Kim W, Kim DH, Lee CJ, Kang SH, et al. Antihypertensive drugs and the risk of Cancer: a Nationwide Cohort Study. J Clin Med. 2021;10. https://doi.org/10.3390/jcm10040771. Santala EEE, Artama M, Pukkala E, Visvanathan K, Staff S, Murtola TJ. Antihypertensive Drug Use and the risk of Ovarian Cancer Death among Finnish Ovarian Cancer Patients-A Nationwide Cohort Study. Cancers (Basel). 2021;13. https://doi.org/10.3390/cancers13092087. Cui Y, Wen W, Zheng T, Li H, Gao YT, Cai H, You M, Gao J, Yang G, Zheng W, et al. Use of Antihypertensive Medications and Survival Rates for breast, colorectal, lung, or stomach Cancer. Am J Epidemiol. 2019;188:1512–28. https://doi.org/10.1093/aje/kwz106. Harding BN, Delaney JA, Urban RR, Weiss NS. Post-diagnosis use of antihypertensive medications and the risk of death from ovarian cancer. Gynecol Oncol. 2019;154:426–31. https://doi.org/10.1016/j.ygyno.2019.05.030. Kobara H, Fujihara S, Iwama H, Matsui T, Fujimori A, Chiyo T, Tingting S, Kobayashi N, Nishiyama N, Yachida T, et al. Antihypertensive drug telmisartan inhibits cell proliferation of gastrointestinal stromal tumor cells in vitro. Mol Med Rep. 2020;22:1063–71. https://doi.org/10.3892/mmr.2020.11144. Fujita N, Fujita K, Iwama H, Kobara H, Fujihara S, Chiyo T, Namima D, Yamana H, Kono T, Takuma K, et al. Antihypertensive drug telmisartan suppresses the proliferation of gastric cancer cells in vitro and in vivo. Oncol Rep. 2020;44:339–48. https://doi.org/10.3892/or.2020.7607. Williams NM, Vincent LT, Rodriguez GA, Nouri K. Antihypertensives and melanoma: an updated review. Pigment Cell Melanoma Res. 2020;33:806–13. https://doi.org/10.1111/pcmr.12918. Saikawa S, Kaji K, Nishimura N, Seki K, Sato S, Nakanishi K, Kitagawa K, Kawaratani H, Kitade M, Moriya K, et al. Angiotensin receptor blockade attenuates cholangiocarcinoma cell growth by inhibiting the oncogenic activity of yes-associated protein. Cancer Lett. 2018;434:120–9. https://doi.org/10.1016/j.canlet.2018.07.021. Samukawa E, Fujihara S, Oura K, Iwama H, Yamana Y, Tadokoro T, Chiyo T, Kobayashi K, Morishita A, Nakahara M, et al. Angiotensin receptor blocker telmisartan inhibits cell proliferation and tumor growth of cholangiocarcinoma through cell cycle arrest. Int J Oncol. 2017;51:1674–84. https://doi.org/10.3892/ijo.2017.4177. Nakai Y, Isayama H, Sasaki T, Takahara N, Saito K, Takeda T, Umefune G, Saito T, Takagi K, Watanabe T, et al. No Survival Benefit from the inhibition of renin-angiotensin system in biliary Tract Cancer. Anticancer Res. 2016;36:4965–70. https://doi.org/10.21873/anticanres.11065. Gunchick V, McDevitt RL, Choi E, Winslow K, Zalupski MM, Sahai V. Survival analysis of 1140 patients with biliary Cancer and Benefit from Concurrent Renin-Angiotensin Antagonists, Statins, or aspirin with systemic therapy. Oncologist. 2023;28:531–41. https://doi.org/10.1093/oncolo/oyad063.